Member Info for Timster

RNS tomorrow then, as per mrR's sauce

Excellent news you must relish your special sauces

Thanks mayt, I've filtered you for this pointless post

And they are on Thursdays and we are 9 weeks into cohort 4, cohort 3 was a nine weeker...

Exciting times...

Bloody deramping beintruantwinnifret

I thought there would be an RNS to confirm the acquisition is complete. Appears it is though from this post and the launch D website.

But if they did insist on a 5th cohort the I'd guess 1b couldn't start as the point of 1a is to determine a dose level for 1b so that could be at the level of cohort 5 for example.

Is that what the chart says? Amazing insight

Meeting just finished?

Those assays will be vastly improved soon, with the use of affimers

I don't think they'll be another, I think they'll be an RNS stating 1a complete, MTD not reached , phase 1b now recruiting at x dosage.
Data to be presented in the science day on x November.

But who knows, it's all guessing

Who gives a fluck about and interview Monday when today is the day the safety committee meet and Fiona presenting Saturday (pre clinical obviously)

Says the man who sold at 117

Does it really matter ?

I would suggest "expectations for outcomes of phase 1a" would be covered by Fiona in Saturday.

And the Paul hill interview already covered it
https://youtu.be/PWrjyiR-r6o

Dose escalation RNS'S come on a Thursday.

9 weeks into cohort 4, will we get one tomorrow?

Either

New DE
Or
Phase 1a complete

Great news, hope he's not lying, he doesn't seem the lying type though...

I think the question was more about why anxious trader is comparing avactas position now, over a year into a p1a trial of ava6000 to the "LFT incident"

Meets on a Wednesday

Definitely wressmycash

Yesterday does show that on actual good news people will pile in having no idea why but following the shouts of £10 a share, that alone may push us well beyond the 2 quid mark.

Then you have the "intelligent" investors who will understand the magnitude of decent phase 1a data and push us further.